Following the company’s recent announcement of their six month interim results, CEO Martin Gouldstone, speaks to Paul Hill of Vox Markets and discusses:
- What the company does and the future growth in precision medicine
- New application area in human longevity/ageing
- Current client demand
- Update on ONC’s commercialisation/turnaround strategy
- Outlook & goals for FY25
- Cash runway ahead
View the interview below: